BG60261B2 - Lon-acting formulation of cefaclor - Google Patents

Lon-acting formulation of cefaclor

Info

Publication number
BG60261B2
BG60261B2 BG65844A BG6584484A BG60261B2 BG 60261 B2 BG60261 B2 BG 60261B2 BG 65844 A BG65844 A BG 65844A BG 6584484 A BG6584484 A BG 6584484A BG 60261 B2 BG60261 B2 BG 60261B2
Authority
BG
Bulgaria
Prior art keywords
active substance
slowly
formulation form
cefaclor
lon
Prior art date
Application number
BG65844A
Other languages
Bulgarian (bg)
English (en)
Other versions
BG60261B1 (bg
Inventor
Teruo Sakamoto
Sadao Kawai
Kinzaburo Noda
Toyohiko Takeda
Hiroshi Kato
Original Assignee
Shionogi & Co.Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi & Co.Ltd. filed Critical Shionogi & Co.Ltd.
Publication of BG60261B1 publication Critical patent/BG60261B1/bg
Publication of BG60261B2 publication Critical patent/BG60261B2/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BG65844A 1983-06-15 1984-06-13 Lon-acting formulation of cefaclor BG60261B2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP58108289A JPS601128A (ja) 1983-06-15 1983-06-15 作用持続型セフアクロル製剤

Publications (2)

Publication Number Publication Date
BG60261B1 BG60261B1 (bg) 1994-03-31
BG60261B2 true BG60261B2 (en) 1994-03-31

Family

ID=14480890

Family Applications (1)

Application Number Title Priority Date Filing Date
BG65844A BG60261B2 (en) 1983-06-15 1984-06-13 Lon-acting formulation of cefaclor

Country Status (23)

Country Link
US (1) US4713247A (cg-RX-API-DMAC7.html)
EP (1) EP0129382B1 (cg-RX-API-DMAC7.html)
JP (1) JPS601128A (cg-RX-API-DMAC7.html)
KR (1) KR910004573B1 (cg-RX-API-DMAC7.html)
AT (1) ATE56869T1 (cg-RX-API-DMAC7.html)
AU (1) AU568654B2 (cg-RX-API-DMAC7.html)
BG (1) BG60261B2 (cg-RX-API-DMAC7.html)
CA (1) CA1213218A (cg-RX-API-DMAC7.html)
DD (1) DD216163A5 (cg-RX-API-DMAC7.html)
DE (1) DE3483282D1 (cg-RX-API-DMAC7.html)
DK (2) DK291884A (cg-RX-API-DMAC7.html)
ES (1) ES8602407A1 (cg-RX-API-DMAC7.html)
FI (1) FI84556C (cg-RX-API-DMAC7.html)
GB (1) GB2141342B (cg-RX-API-DMAC7.html)
GR (1) GR81598B (cg-RX-API-DMAC7.html)
HU (1) HU193434B (cg-RX-API-DMAC7.html)
IE (1) IE58278B1 (cg-RX-API-DMAC7.html)
IL (1) IL72083A (cg-RX-API-DMAC7.html)
NZ (1) NZ208345A (cg-RX-API-DMAC7.html)
PH (1) PH19902A (cg-RX-API-DMAC7.html)
PT (1) PT78699B (cg-RX-API-DMAC7.html)
RO (1) RO88924A (cg-RX-API-DMAC7.html)
ZA (1) ZA844357B (cg-RX-API-DMAC7.html)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5229132A (en) * 1985-02-22 1993-07-20 Grimberg Georges Serge Non-absorbable gastrointestinal medicament provided for treating the two levels of the digestive tract at the same time
JPS61210025A (ja) * 1985-03-14 1986-09-18 Teisan Seiyaku Kk 安定化された抗生物質複合顆粒製剤
AU591248B2 (en) * 1986-03-27 1989-11-30 Kinaform Technology, Inc. Sustained-release pharaceutical preparation
JPS62226926A (ja) * 1986-03-27 1987-10-05 Teisan Seiyaku Kk 持続性複合顆粒剤
JPH0714863B2 (ja) * 1986-06-02 1995-02-22 忠生 白石 時差溶解性の入浴剤
NZ223619A (en) * 1987-02-27 1990-10-26 Lilly Co Eli Sustained release tablet containing cefaclor, a hydrophilic polymer and an acrylic polymer
US4968508A (en) * 1987-02-27 1990-11-06 Eli Lilly And Company Sustained release matrix
BE1002079A4 (fr) * 1988-07-01 1990-06-19 S M B Lab Composition pharmaceutique d'erythromycine a liberation prolongee, sa preparation et son utilisation.
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5122384A (en) * 1989-05-05 1992-06-16 Kv Pharmaceutical Company Oral once-per-day organic nitrate formulation which does not induce tolerance
CA2085342A1 (en) * 1990-06-14 1991-12-15 Milton R. Kaplan Stable aqueous drug suspensions
GB9318641D0 (en) * 1993-09-08 1993-10-27 Edko Trading Representation Compositions
ES2079327B1 (es) * 1994-12-13 1996-08-01 Lilly Sa Formulaciones farmaceuticas de cefaclor.
WO1997033569A1 (de) * 1996-03-13 1997-09-18 LABTEC Gesellschaft für technologische Forschung und Entwicklung mbH Arzneimittelzubereitung für ace-hemmer
US5948440A (en) * 1997-12-17 1999-09-07 Ranbaxy Laboratories Limited Modified release matrix formulation of cefaclor and cephalexin
ZA98728B (en) * 1998-01-29 1998-10-28 Ranbaxy Lab Ltd Modified release matrix formulations of cefactor and cephalexin
KR100296413B1 (ko) * 1998-04-01 2001-11-14 김선진 세파클러함유서방성정제
US20030170181A1 (en) * 1999-04-06 2003-09-11 Midha Kamal K. Method for preventing abuse of methylphenidate
US6340476B1 (en) 1999-04-06 2002-01-22 Armaquest, Inc. Pharmaceutical dosage form for pulsatile delivery of methylphenidate
EP1180022A4 (en) * 1999-05-14 2004-01-07 Lilly Co Eli PROCESS FOR THE MASS PRODUCTION OF PHARMACEUTICAL MATERIAL WITH UNIFORM SOLUBILITY
US6596307B1 (en) 1999-06-15 2003-07-22 Eli Lilly And Company Process for preparing pharmaceutical bulk material having uniform dissolution
US6991807B2 (en) * 2000-02-24 2006-01-31 Advancis Pharmaceutical, Corp. Antibiotic composition
EP1267765A4 (en) * 2000-02-24 2008-12-24 Middlebrook Pharmaceuticals In ANTIBIOTIC AND MUSHROOM AGENTS
WO2001062231A1 (en) * 2000-02-24 2001-08-30 Advancis Pharmaceutical Corporation Antibiotic composition with inhibitor
US7025989B2 (en) * 2000-02-24 2006-04-11 Advancis Pharmaceutical Corp. Multiple-delayed released antibiotic product, use and formulation thereof
AU2001239838A1 (en) * 2000-02-24 2001-09-03 Advancis Pharmaceutical Corporation Therapeutic product, use and formulation thereof
EP1353651A2 (en) * 2001-01-18 2003-10-22 Natco Pharma Limited Extended release pharmaceutical compositions containing beta-lactam antibiotics
JP2005526059A (ja) * 2002-03-07 2005-09-02 アドバンシス ファーマスーティカル コーポレイション 抗生物質組成物
WO2003094899A1 (es) * 2002-05-09 2003-11-20 Diffucap-Chemobras Química E Farmacéutica, Ltda. Nuevo procedimiento para la preparacion de composiciones de liberacion programada conteniendo (s) -1- [n-[1-(ethoxycarbonyl)-3-phenylpropyl]-l-alanyl]-l-proline, y al producto obtenido por dicho procedimiento
AU2004258953B2 (en) * 2003-07-21 2011-02-10 Shionogi, Inc. Antibiotic product, use and formulation thereof
EP1648418A4 (en) * 2003-07-21 2011-11-16 Middlebrook Pharmaceuticals Inc ANTIBIOTIC PRODUCT, ITS USE AND FORMULATION
JP2006528189A (ja) * 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション 抗生物質産物、その使用法および製剤
EP1653924A4 (en) * 2003-08-12 2009-09-09 Middlebrook Pharmaceuticals In ANTIBIOTICS, USE AND FORMULATION ASSOCIATED
US8246996B2 (en) * 2003-08-29 2012-08-21 Shionogi Inc. Antibiotic product, use and formulation thereof
CA2538064C (en) * 2003-09-15 2013-12-17 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
AU2003290394A1 (en) * 2003-09-30 2005-04-14 Lupin Ltd. Extended release formulation of beta-lactam antibiotics
MX2007012763A (es) * 2005-04-12 2008-01-14 Elan Pharma Int Ltd Composiciones de liberacion controlada que comprenden una cefalosporina para el tratamiento de infeccion bacteriana.
US20060287212A1 (en) * 2005-06-02 2006-12-21 Novozymes A/S Blends of inactive particles and active particles
JP2008545841A (ja) 2005-06-02 2008-12-18 ノボザイムス アクティーゼルスカブ 不活性粒子及び活性粒子のブレンド
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
PE20120654A1 (es) 2009-05-19 2012-05-31 Celgene Corp Formulaciones de 4-amino-2-(2,6-dioxopiperidin-1,3-il) isoindolin-1,3-diona
MX2014007312A (es) * 2011-12-19 2014-08-27 Salix Pharmaceuticals Ltd Metodos para el tratamiento y la prevencion de estreñimiento inducido por opioides usando composiciones orales de metilnaltrexona.
CA2936748C (en) 2014-10-31 2017-08-08 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
CN104688701A (zh) * 2015-03-20 2015-06-10 江苏亚邦强生药业有限公司 一种头孢克洛片剂及其制备方法
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
CN110408670A (zh) * 2019-08-19 2019-11-05 苏州盛达药业有限公司 一种酶催化合成头孢克洛的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2738303A (en) * 1952-07-18 1956-03-13 Smith Kline French Lab Sympathomimetic preparation
US3906086A (en) * 1971-07-19 1975-09-16 Richard G Powers Timed-release aspirin
JPS52139713A (en) * 1976-05-13 1977-11-21 Shionogi & Co Ltd Sustained release cefalexin preparations
US4250166A (en) * 1977-05-27 1981-02-10 Shionogi & Co., Ltd. Long acting preparation of cefalexin for effective treatments of bacterial infection sensitive to cefalexin
GR74995B (cg-RX-API-DMAC7.html) * 1980-08-27 1984-07-12 Ciba Geigy Ag
JPS5826816A (ja) * 1981-08-11 1983-02-17 Teisan Seiyaku Kk 球形顆粒からなる持続性複合顆粒剤

Also Published As

Publication number Publication date
BG60261B1 (bg) 1994-03-31
FI842406L (fi) 1984-12-16
RO88924A (ro) 1986-04-30
ES533901A0 (es) 1985-12-01
IE841444L (en) 1984-12-15
GB2141342A (en) 1984-12-19
DK291884D0 (da) 1984-06-14
PT78699B (en) 1986-07-15
EP0129382B1 (en) 1990-09-26
EP0129382A3 (en) 1986-07-09
HU193434B (en) 1987-10-28
PH19902A (en) 1986-08-13
IE58278B1 (en) 1993-08-25
IL72083A0 (en) 1984-10-31
FI84556B (fi) 1991-09-13
JPS6232166B2 (cg-RX-API-DMAC7.html) 1987-07-13
ZA844357B (en) 1985-06-26
KR910004573B1 (ko) 1991-07-06
NZ208345A (en) 1986-12-05
US4713247A (en) 1987-12-15
GB2141342B (en) 1986-11-12
AU568654B2 (en) 1988-01-07
GB8414633D0 (en) 1984-07-11
HUT34692A (en) 1985-04-28
DE3483282D1 (de) 1990-10-31
AU2941884A (en) 1984-12-20
ATE56869T1 (de) 1990-10-15
EP0129382A2 (en) 1984-12-27
CA1213218A (en) 1986-10-28
JPS601128A (ja) 1985-01-07
DK170922B1 (da) 1996-03-18
GR81598B (cg-RX-API-DMAC7.html) 1984-12-11
PT78699A (pt) 1985-01-01
DD216163A5 (de) 1984-12-05
ES8602407A1 (es) 1985-12-01
KR850000242A (ko) 1985-02-26
DK291884A (da) 1984-12-16
FI842406A0 (fi) 1984-06-13
FI84556C (fi) 1991-12-27
IL72083A (en) 1987-10-30

Similar Documents

Publication Publication Date Title
BG60261B2 (en) Lon-acting formulation of cefaclor
US4376118A (en) Stable nonaqueous solution of tetracycline salt
GB8524275D0 (en) Pharmaceutical & dietary compositions
ES8201596A1 (es) Procedimiento de obtencion de mucopolisacaridos
IE830207L (en) Fibrinogen formulation
SE8402551L (sv) Cinnamoylmoranolin-derivat
MY101791A (en) New benzimidazole derivatives
ES2032382T3 (es) Metodo para preparar un medicamento para la prevencion o tratamiento de la endometriosis.
PL268927A1 (en) Method of obtaining novel derivatives of benzimidazole
DE3766200D1 (de) L-dopa enthaltendes arzneimittel.
DE59410151D1 (de) Feste Flupirtin enthaltende orale Darreichungsformen mit kontrollierter Wirkstoffabgabe
EP0173664A3 (en) Biologically active benzimidazole compounds and process for their preparation
TNSN90021A1 (fr) Procede de preparation de tetrahydroimidazo (1,4) benzodiazepin -2- thiones antivirales
HUT57204A (en) Process for producing 4-fluoro-2-///4-methoxy-2-pyridinyl/-methyl/-sulfinyl/-1h-benzimidazol with gastric acid secration-diminishing activity and pharmaceutical compositions containing them
ES8705763A1 (es) Procedimiento para preparar nuevas formulaciones de gel parafines terapeuticos y diagnosticos
DE2963545D1 (en) Pharmaceutical composition containing all-e- or 13-z-7,8-dehydro-retinoic acid and process for its preparation
JPS52156932A (en) Remedy for diabetes
KR900016130A (ko) 2-피리딜메틸티오 유도체 및 궤양 치료제
ATE39697T1 (de) Erythromycin-a-salz mit mucosecretolytischer und fluidisierender aktivitaet, verfahren zu seiner herstellung und dieses enthaltende pharmazeutische zusammensetzungen.
SU1438434A1 (ru) Способ определения активности гормона тимуса
JPS56123919A (en) Remedy and preventive for diabetes
GB1304707A (cg-RX-API-DMAC7.html)
IT1186775B (it) Derivati nuobosidici aventi proprieta' antierpetiche,composizioni farmaceutiche che li contengono e procedimento per la preparazione degli ingredienti attivi
JPS54132219A (en) Immunoactivating agent
GB1472816A (en) Circulatory pharmaceutical compositions containing tetrahydroal stonine